申请人:Janssen Pharmaceutica, N.V.
公开号:US05824682A1
公开(公告)日:1998-10-20
The present invention is concerned with compounds of formula ##STR1## the pharmaceutically acceptable acid addition salts thereof, and the stereochemically isomeric forms thereof, wherein R.sup.1 is hydrogen or C.sub.1-6 alkyl; R.sup.2 is hydrogen or C.sub.1-6 alkyl; R.sup.3 is hydrogen or C.sub.1-6 alkyl; R.sup.4 is hydrogen, halo, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkyloxy, aryloxy or arylmethoxy; R.sup.5 and R.sup.6 designate R.sup.5a and R.sup.6a wherein R.sup.5a and R.sup.6a taken together form a bivalent radical; or R.sup.5 and R.sup.6 can designate R.sup.5b and R.sup.6b wherein R.sup.5b is hydrogen and R.sup.6b is a heterocycle or an optionally substituted alkenyl or alkynyl group; or R.sup.5 and R.sup.6 designate R.sup.5c and R.sup.6c, wherein R.sup.5c and R.sup.6c are hydrogen, halo, C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, hydroxy, C.sub.1-6 alkyloxy, cyano, aminoC.sub.1-6 alkyl, carboxyl, C.sub.1-6 alkyloxycarbonyl, nitro, amino, aminocarbonyl, C.sub.1-6 alkylcarbonylamino, or mono-di(C.sub.1-6 alkyl)amino; Q is a heterocyclic ring containing at least one nitrogen atom or a radical of formula ##STR2## pharmaceutical compositions, preparations and use as a medicine are also described.
本发明涉及式为##STR1##的化合物,其药学上可接受的酸盐,以及其立体异构体,其中R.sup.1是氢或C.sub.1-6烷基;R.sup.2是氢或C.sub.1-6烷基;R.sup.3是氢或C.sub.1-6烷基;R.sup.4是氢,卤素,C.sub.1-6烷基,羟基,C.sub.1-6烷氧基,芳氧基或芳基甲氧基;R.sup.5和R.sup.6指R.sup.5a和R.sup.6a,其中R.sup.5a和R.sup.6a结合形成双价基团;或者R.sup.5和R.sup.6可以指R.sup.5b和R.sup.6b,其中R.sup.5b是氢,R.sup.6b是杂环或可选取代的烯丙基或炔基基团;或者R.sup.5和R.sup.6指R.sup.5c和R.sup.6c,其中R.sup.5c和R.sup.6c是氢,卤素,C.sub.1-6烷基,C.sub.3-6烯基,C.sub.3-6炔基,羟基,C.sub.1-6烷氧基,氰基,氨基C.sub.1-6烷基,羧基,C.sub.1-6烷氧基羰基,硝基,氨基,氨基羰基,C.sub.1-6烷基羰基氨基,或单-二(C.sub.1-6烷基)氨基;Q是含有至少一个氮原子的杂环或式##STR2##的基团,还描述了制药组合物、制剂和作为药物的用途。